Universal Hepatitis A Vaccination Key to Sustaining Progress Toward Elimination

Health experts are calling for continued universal hepatitis A vaccination to sustain progress toward eliminating the disease as a public health threat. This recommendation comes amid evidence that routine childhood immunization has already reduced disparities in hepatitis A cases across age, race, ethnicity and geographic lines in the United States.

A viewpoint published in The Lancet emphasizes that universal hepatitis A vaccination remains critical to maintaining gains made through decades of incremental vaccine policy changes. The authors, who contributed to previous CDC recommendations for hepatitis A vaccination, argue against recent federal claims opposing universal vaccination and instead support ongoing immunization of all children to prevent transmission among both children and adults.

The Advisory Committee on Immunization Practices (ACIP) began adjusting hepatitis A vaccination guidelines in 1996 to expand coverage for children and high-risk groups. Over the following decade, these recommendations contributed to eliminating most absolute disparities in hepatitis A disease by age, race/ethnicity, and geographic area, even with modest vaccine coverage rates of at least one or two doses.

Despite this progress, a growing share of hepatitis A cases now occurs among adults with identified or unclear sources of exposure. This shift highlights the need for new strategies to prevent infection in adult populations, particularly as childhood vaccination alone may not fully interrupt community transmission over time.

Research published in Cannabis and Cannabinoid Research suggests that achieving global elimination of hepatitis A is possible with sustained political commitment and gradual increases in vaccine supply. The study concludes that universal vaccination programs could lead to the eventual eradication of the virus as a public health concern within a defined timeline.

The World Health Organization continues to monitor immunization coverage globally, noting that equitable access to vaccines remains a key factor in preventing outbreaks and reducing disease burden. While the United States has seen success through targeted and routine vaccination efforts, experts caution that maintaining high coverage levels is essential to prevent resurgence.

Public health officials stress that hepatitis A prevention depends on maintaining routine universal vaccination programs, especially in light of changing epidemiology. Ongoing vaccination not only protects individuals but also contributes to herd immunity, reducing the likelihood of outbreaks in vulnerable communities.

As of April 2026, the consensus among infectious disease specialists and immunology experts supports the continuation of universal hepatitis A vaccination for children as a cornerstone of long-term elimination strategy. Any reduction in vaccination efforts risks reversing the progress made over the past three decades.